Schrodinger/$SDGR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Schrodinger
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Ticker
$SDGR
Sector
Primary listing
Employees
891
Headquarters
Website
Schrodinger Metrics
BasicAdvanced
$1.5B
-
-$2.48
1.74
-
Price and volume
Market cap
$1.5B
Beta
1.74
52-week high
$28.47
52-week low
$16.60
Average daily volume
1.2M
Financial strength
Current ratio
3.3
Quick ratio
3.126
Long term debt to equity
28.428
Total debt to equity
33.34
Profitability
EBITDA (TTM)
-186.484
Gross margin (TTM)
58.48%
Net profit margin (TTM)
-76.22%
Operating margin (TTM)
-81.09%
Effective tax rate (TTM)
-0.66%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-17.52%
Return on equity (TTM)
-44.40%
Valuation
Price to revenue (TTM)
6.407
Price to book
4.48
Price to tangible book (TTM)
4.54
Price to free cash flow (TTM)
62.549
Free cash flow yield (TTM)
1.60%
Free cash flow per share (TTM)
0.334
Growth
Revenue change (TTM)
18.59%
Earnings per share change (TTM)
-11.04%
3-year revenue growth (CAGR)
13.40%
3-year earnings per share growth (CAGR)
6.03%
What the Analysts think about Schrodinger
Analyst ratings (Buy, Hold, Sell) for Schrodinger stock.
Bulls say / Bears say
Q2 2025 total revenue increased 16% year-over-year to $54.8 million, beating consensus expectations of $52.03 million, driven by 15% growth in software and 19% growth in drug discovery (GuruFocus News)
Net loss narrowed to $43.2 million in Q2 2025 from $54.0 million in the previous year, with EPS at -$0.59 surpassing the estimate of -$0.88, showing improved operational efficiency (GuruFocus News)
The company ended Q2 2025 with $462 million in cash and equivalents, providing a strong foundation to support its software expansion and drug discovery pipeline (Investing.com)
Software gross margin fell to 68% in Q2 2025 from 80% a year earlier, pressured by costs related to the predictive toxicology initiative (GuruFocus News)
Total operating expenses remained high at $79.1 million in Q2 2025, despite a 6% year-over-year reduction, extending the company’s cash burn risk (The Motley Fool)
Drug discovery revenue growth partially reflects recognition of a one-time $150 million upfront payment from the Novartis collaboration, raising concerns about future sustainability when milestone payments slow (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Schrodinger Financial Performance
Revenues and expenses
Schrodinger Earnings Performance
Company profitability
Schrodinger News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Schrodinger stock?
Schrodinger (SDGR) has a market cap of $1.5B as of October 22, 2025.
What is the P/E ratio for Schrodinger stock?
The price to earnings (P/E) ratio for Schrodinger (SDGR) stock is 0 as of October 22, 2025.
Does Schrodinger stock pay dividends?
No, Schrodinger (SDGR) stock does not pay dividends to its shareholders as of October 22, 2025.
When is the next Schrodinger dividend payment date?
Schrodinger (SDGR) stock does not pay dividends to its shareholders.
What is the beta indicator for Schrodinger?
Schrodinger (SDGR) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.